30 closest matches · ranked by relevance
Acute Lymphoblastic Leukemia · Acute Myelogenous Leukemia · Chronic Myelogenous Leukemia
Primary: Antibody Recall Response Rate — 0.167 proportion of participants
Heart Failure
Primary: Sustained Virologic Response After Treatment — 24 Participants
Myeloproliferative Disorders · Acute Myelogenous Leukemia · Chronic Myelogenous Leukemia
Primary: Number of Participants Who Experienced Transplant Related Mortality — 5; 4 Participants
Liver Transplant · Hepatitis C
Primary: Adverse Events Due to Sofosbuvir/Velpatasvir (Epclusa) — 0; 0 Participants
MDS (Myelodysplastic Syndrome) · Myeloproliferative Disorder · Lymphoma, Non-Hodgkin
Primary: Overall Survival — 36 Participants
EBV Viremia · CMV Viremia
Primary: Incidence of EBV or CMV Related Disease in Transplant Recipient — 2; 0 participants
Renal Failure Chronic · Hepatitis C
Primary: Number of Participants With Undetectable HCV — 30 Participants
Kidney Transplant · Hepatitis C · HCV
Primary: Proportion of Patients With Undetectable Hepatitis C Virus (HCV) Polymerase Chain Reaction (PCR) at 12 Weeks After Completion of HCV Treatment — 28 Participants
Acute Lymphocytic Leukemia · Acute Myelogenous Leukemia · Burkitt's Lymphoma
Primary: Percentage of Participants With Progression Free Survival (PFS) — 35.0; 41.1 percentage of participants — p=0.4092
Cardiovascular Diseases
Primary: Brachial Artery Flow-mediated Dilation (FMD) After Fresh Red Blood Cells (RBCs) Transfusions vs. Storage-aged Red Blood Cells (saRBCs) Transfusions at Baseline — 4.87…
Anemia
Primary: Number of Participants That Had bRBC Detectable at 70 Days Post-intervention — 5 participants
Leukemia · Myeloproliferative Disorders · Myelodysplastic-Myeloproliferative Diseases
Primary: Two-year Overall Survival — 46; 51 percentage of patients
Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia · Aggressive Non-Hodgkin Lymphoma
Primary: Overall Survival — 35 percent of patients
CML (Chronic Myelogenous Leukemia) · CLL (Chronic Lymphocytic Leukemia) · AML (Acute Myelogenous Leukemia)
Primary: To Determine if Selective T Cell Depletion Using the Photodepletion Procedure Can Substantially Reduce the Rate of Severe Acute GVHD (Grade III/IV) After Matched Sibling…
Leukemia · Lymphoma · Myelodysplastic Syndromes
Primary: Rates of Durable Engraftment — 17.9; 15.75; 13; 18.25 days
Lymphoma, Non-Hodgkin
Primary: Progression-Free Survival (PFS) — 73 percentage of participants
Hematologic Malignancies · Bone Marrow Transplant Rejection
Primary: The Proportion of Patients Who Develop Full Donor T Cell Chimerism at Day 30 — 44.9 percentage of participants
Kidney Disease
Primary: Number of Participants With Live Kidney Donor Activation Events — 87; 86; 88; 5 Participants
Blood Component Transfusion
Primary: Number of Participants With Changes in the Production of Antibody to HLA Antigens — 2; 6; 2; 5 Participants
Lung Diseases
Primary: Subject Sustained Virologic Response (SVR-12) at 12-weeks Post-treatment — 10 Participants
Ischemia Reperfusion Injury
Primary: Lowest 5 Minutes Post-reperfusion Mean Arterial Blood Pressure — 66.03; 57.75 mmHg
Cytomegalovirus
Primary: Number of Participants With a Complete Response — 8; 50 Participants
Kidney Transplant
Primary: Percent of Patients With at Least One Inquiry From a Potential Living Donor — 15.63; 15.63; 15.77; 15.87 percentage of participants
Leukemia · Lymphoma · HIV
Primary: Percentage of Participants With Non-Relapse Mortality — 0.0; 11.8; 18.3 percentage of participants
Multiple Myeloma
Primary: Proportion of Participants With Relapsed Multiple Myeloma With Progression-free (PFS) — 0.31 Proportion of participants PFS
Acute Biphenotypic Leukemia · Acute Lymphoblastic Leukemia · Acute Myeloid Leukemia
Primary: Overall Survival — 28; 15; 53; 7 Participants
Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Leukemia, Myeloid, Acute · Burkitt Lymphoma
Primary: Overall Survival at 180 Days From the Time of Transplant — 83.7; 62.0 percentage of participants
Myelodysplastic Syndrome · Hodgkin's Lymphoma · Non-Hodgkin's Disease
Primary: Percentage of Participants With Grade II-IV Acute Graft Versus Host Disease (GVHD) — 42; 38 percentage of participants
Leukemia, Acute Lymphocytic (ALL) · Leukemia, Myeloid, Acute(AML) · Leukemia, Myeloid, Chronic(CML)
Primary: Event-free Survival (EFS) — 54.8 Percentage of participants
Anemia of Prematurity
Primary: Change in Superior Mesenteric Artery Blood Flow Velocity From Pre-to-post Feed in the Anemic and the Transfused States — 2.02; 5.91; 7.66; 14.99 cm/sec — p=0.571